Oncology company Novocure (NASDAQ: NVCR) announced on Wednesday that it will present new data on its Tumor Treating Fields (TTFields) therapy at the 2025 European Association of Neuro-Oncology (EANO) Meeting in Prague, Czech Republic, from 16-19 October, and at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from 17-21 October.

At EANO 2025, Novocure will share pre-clinical findings demonstrating how TTFields therapy enhances the radiosensitivity of glioblastoma cells by downregulating DNA repair pathways. At ESMO 2025, the company will present a post-hoc analysis from its Phase 3 PANOVA-3 trial, which assessed TTFields used with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The analysis examined treatment efficacy based on device usage and levels of cancer antigen (CA) 19-9.

TTFields therapy uses electric fields to disrupt cancer cell division without significantly affecting healthy cells. Novocure's commercialized TTFields therapies are approved for glioblastoma, non-small cell lung cancer, and malignant pleural mesothelioma, with additional trials underway across multiple solid tumour types.

Headquartered in Baar, Switzerland, Novocure operates US headquarters in Portsmouth, New Hampshire, and research facilities in Haifa, Israel.